83_FR_58488 83 FR 58265 - Government-Owned Inventions; Availability for Licensing

83 FR 58265 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 223 (November 19, 2018)

Page Range58265-58265
FR Document2018-25194

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development.

Federal Register, Volume 83 Issue 223 (Monday, November 19, 2018) 
[Federal Register Volume 83, Number 223 (Monday, November 19, 2018)]
[Notices]
[Page 58265]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-25194]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Sickle Cell Anemia Treatment Through RIOK3 Inhibition

    Available for licensing and commercial development are methods for 
the treatment of beta-globinapathies such as sickle cell disease and 
beta-thalassemia by inhibiting the expression and/or activity of RIOK3 
in erythroid cells such as primary erythroid progenitor cell or a CD34+ 
erythroid cells. RIOK3 inhibitors contemplated within the scope of the 
invention can be antibodies, siRNAs, microRNAs, antisense 
oligonucleotides or small molecules like Midostaurin, Axitinib, 
Bosutinib, or Ruxolitinib.

Potential Commercial Applications:

 Sickle cell disease
 beta thalassemia

Development Stage:

 Early stage
    Inventors: Bjorg Gudmundsdottir, Laxminath Tumburu, John Tisdale 
(all of NHLBI)
    Intellectual Property: HHS Reference No. E-200-2018; U.S 
Provisional Patent Application 62/756,497 filed November 6, 2018.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: November 7, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-25194 Filed 11-16-18; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 223 / Monday, November 19, 2018 / Notices 58265 Podcasting website (http:// Center Drive, Room 7W444, Bethesda, MD SUPPLEMENTARY INFORMATION: videocast.nih.gov). 20892, 240–276–6340, grayp@mail.nih.gov. Technology description follows. A portion of the National Cancer Any interested person may file written comments with the committee by forwarding Sickle Cell Anemia Treatment Through Advisory Board meeting will be closed the statement to the Contact Person listed on RIOK3 Inhibition to the public in accordance with the this notice. The statement should include the Available for licensing and provisions set forth in section name, address, telephone number and when 552b(c)(6), Title 5 U.S.C., as amended, commercial development are methods applicable, the business or professional for the review, discussion, and affiliation of the interested person. for the treatment of beta-globinapathies evaluation of individual intramural In the interest of security, NIH has such as sickle cell disease and beta- programs and projects conducted by the instituted stringent procedures for entrance thalassemia by inhibiting the expression National Cancer Institute, including onto the NCI-Shady Grove campus. All and/or activity of RIOK3 in erythroid consideration of personnel visitors will be asked to show one form of cells such as primary erythroid qualifications and performance, and the identification (for example, a government- progenitor cell or a CD34+ erythroid issued photo ID, driver’s license, or passport) cells. RIOK3 inhibitors contemplated competence of individual investigators, and to state the purpose of their visit. the disclosure of which would within the scope of the invention can be Information is also available on the constitute a clearly unwarranted Institute’s/Center’s home page: NCAB: http:// antibodies, siRNAs, microRNAs, invasion of personal privacy. deainfo.nci.nih.gov/advisory/ncab/ncab.htm, antisense oligonucleotides or small BSA: http://deainfo.nci.nih.gov/advisory/ molecules like Midostaurin, Axitinib, Name of Committee: National Cancer Advisory Board, Ad Hoc Subcommittee on bsa/bsa.htm, where an agenda and any Bosutinib, or Ruxolitinib. Global Cancer Research. additional information for the meeting will be posted when available. Potential Commercial Applications: Open: December 3, 2018, 5:30 p.m. to 7:00 p.m. (Catalogue of Federal Domestic Assistance • Sickle cell disease Agenda: Discussion on Global Cancer Program Nos. 93.392, Cancer Construction; • beta thalassemia Research. 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Development Stage: Place: Gaithersburg Marriott Washingtonian Center, 9751 Washington Diagnosis Research; 93.395, Cancer • Early stage Boulevard, Gaithersburg, MD 20878. Treatment Research; 93.396, Cancer Biology Inventors: Bjorg Gudmundsdottir, Contact Person: Dr. Robert T. Croyle, Research; 93.397, Cancer Centers Support; Laxminath Tumburu, John Tisdale (all Acting Executive Secretary, NCAB Ad Hoc 93.398, Cancer Research Manpower; 93.399, of NHLBI) Subcommittee on Global Cancer Research, Cancer Control, National Institutes of Health, Intellectual Property: HHS Reference National Cancer Institute—Shady Grove, HHS) No. E–200–2018; U.S Provisional Patent National Institutes of Health, 9609 Medical Dated: November 14, 2018. Application 62/756,497 filed November Center Drive, Room 4E420, Bethesda, MD Natasha M. Copeland, 6, 2018. 20892, (240) 276–6690, croyler@mail.nih.gov. Licensing Contact: Michael Program Analyst, Office of Federal Advisory Name of Committee: NCI Board of Committee Policy. Shmilovich, Esq, CLP; 301–435–5019; Scientific Advisors and National Cancer shmilovm@mail.nih.gov. Advisory Board. [FR Doc. 2018–25193 Filed 11–16–18; 8:45 am] Open: December 4, 2018, 8:45 a.m. to 4:15 BILLING CODE 4140–01–P Dated: November 7, 2018. p.m. Michael A. Shmilovich, Agenda: Joint meeting of the NCI Board of Senior Licensing and Patenting Manager, Scientific Advisors and National Cancer DEPARTMENT OF HEALTH AND National Heart, Lung, and Blood Institute, Advisory Board—NCI Director’s report, HUMAN SERVICES Office of Technology Transfer and presentations, and review of concepts. Development. Closed: December 4, 2018, 4:15 p.m. to National Institutes of Health [FR Doc. 2018–25194 Filed 11–16–18; 8:45 am] 5:15 p.m. BILLING CODE 4140–01–P Agenda: Review of intramural program site Government-Owned Inventions; visit outcomes and the discussion of Availability for Licensing confidential personnel issues. Place: National Cancer Institute—Shady AGENCY: National Institutes of Health, DEPARTMENT OF HEALTH AND Grove, 9609 Medical Center Drive, Room HHS. HUMAN SERVICES TE406 & 408, Rockville, MD 20850. ACTION: Notice. Contact Person: Paulette S. Gray, Ph.D., National Institutes of Health Director, Division of Extramural Activities, SUMMARY: The inventions listed below National Cancer Institute—Shady Grove, are owned by an agency of the U.S. National Institute of Allergy and National Institutes of Health, 9609 Medical Government and are available for Infectious Diseases; Notice of Closed Center Drive, Room 7W444, Bethesda, MD licensing in the U.S. to achieve Meeting 20892, 240–276–6340, grayp@mail.nih.gov. expeditious commercialization of Pursuant to section 10(d) of the Name of Committee: NCI Board of results of federally-funded research and Scientific Advisors and National Cancer Federal Advisory Committee Act, as Advisory Board. development. amended, notice is hereby given of a Open: December 5, 2018, 9:00 a.m. to 12:45 FOR FURTHER INFORMATION CONTACT: meeting of the Division of Intramural p.m. Licensing information may be obtained Research Board of Scientific Counselors. Agenda: Joint meeting of the NCI Board of by emailing the indicated licensing The meeting will be closed to the Scientific Advisors and National Cancer contact at the National Heart, Lung, and public in accordance with the Advisory Board—Presentations and review of Blood, Office of Technology Transfer provisions set forth in section khammond on DSK30JT082PROD with NOTICES concepts. and Development Office of Technology 552b(c)(6), Title 5 U.S.C., as amended Place: National Cancer Institute—Shady Transfer, 31 Center Drive, Room 4A29, for the review, discussion, and Grove, 9609 Medical Center Drive, Room TE406 & 408, Rockville, MD 20850. MSC2479, Bethesda, MD 20892–2479; evaluation of individual intramural Contact Person: Paulette S. Gray, Ph.D., telephone: 301–402–5579. A signed programs and projects conducted by the Director, Division of Extramural Activities, Confidential Disclosure Agreement may NATIONAL INSTITUTE OF ALLERGY National Cancer Institute—Shady Grove, be required to receive any unpublished AND INFECTIOUS DISEASES, National Institutes of Health, 9609 Medical information. including consideration of personnel VerDate Sep<11>2014 17:20 Nov 16, 2018 Jkt 247001 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\19NON1.SGM 19NON1


Document Created: 2018-11-17 02:46:48
Document Modified: 2018-11-17 02:46:48
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.
FR Citation83 FR 58265 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR